Adjuvant Chemo With Endocrine Therapy for HR+/HER2- Breast Cancer

Although endocrine therapy following surgery is recommended for HR-positive/HER2-negative, axillary node-negative breast cancers, the value of adjuvant chemotherapy in the setting of moderate risk is unclear.